Product category:
Reagents and catalysts
News Release from: Link Technologies
Edited by the Laboratorytalk Editorial
Team on 25 June 2007
Licence to deal in PNA monomers
Peptide nucleic acids (PNAs) have numerous identified and proposed applications in molecular biology procedures, diagnostic assays, as well as antisense and anti-gene therapies.
Link Technologies and PNA Inventor have entered into a non-exclusive licence agreement to allow Link Technologies to manufacture and sell monomers for peptide nucleic acid (PNA) synthesis worldwide under the PNA Inventor Group's patents In terms of the overall research market for PNA technologies, recent estimates predict that PNA synthesis will account for 10% of the global DNA synthesis market by 2010; a market presently worth US$800m and growing at over 10% per year
This article was originally published on Laboratorytalk on 6 Dec 2001 at 8.00am (UK)
Related stories
Akcros invests in solid stabilisers
To meet growing demand for PVC stabilisers, Akcros Chemicals will invest in increased production of the Interlite ZP range of solid mixed metal soap stabilisers at its Eccles, UK, facility
MBO for Akcros
Akzo Nobel plastics and processing additives business unit, making lead stabilisers for polymer products sold, to management, and to trade under the new name Allstab
Peter Nielsen, professor at the University of Copenhagen, speaking on behalf of the PNA Inventor Group said, "We are very pleased to have granted Link a license to make and sell PNA monomers.
"We look forward to cooperating with Link and are confident that the continued availability of high quality PNA monomers will benefit research laboratories".
John Bremner, business development director of Link Technologies, also commented: "Agreement of this licence underlines our commitment to make new and emerging technologies available to our customers.
"We see broadening the access of PNA technology to researchers worldwide as an important part of this strategy".
Initially, Link will be offering the preferred Fmoc/Bhoc protected PNA monomers.
These monomers are compatible with commercial automated oligonucleotide, peptide or combinatorial synthesisers.
It is anticipated that these products will be available from July 2007.
• Link Technologies: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
